Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis

被引:21
|
作者
Evangelopoulos, Maria Eleftheria [1 ]
Koutsis, Georgios [1 ]
Markianos, Manolis [1 ]
机构
[1] Univ Athens, Eginit Hosp, Sch Med, Dept Neurol, 74 Vassilisis Sophias Ave, Athens 11528, Greece
关键词
D O I
10.1155/2014/486282
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several studies have investigated leptin levels in patients with multiple sclerosis (MS) with somewhat conflicting results. They have all focused on patients with established relapsing-remitting (RR) MS but have not specifically looked at patients with clinically isolated syndrome (CIS) suggestive of MS, in the early stages of disease. In this study, serum leptin levels were measured in 89 treatment-naive patients with CIS (53 patients) or RRMS (36 patients) and 73 controls searching for differences between the groups and for associations with several disease parameters. The expected significant sexual dimorphism in leptin levels (higher levels in females) was observed in both MS patients and controls. Increased leptin levels were found in female patients with RRMS compared to female controls (P = .003) and female CIS patients (P = .001). Female CIS patients had comparable levels to controls. Leptin levels correlated positively to disease duration, but not to EDSS, in female patients with RRMS. The results of the present study do not indicate involvement of leptin in the early stages of MS. Normal leptin levels in patients with CIS suggest that leptin does not have a pathogenic role. The ratio leptin/BMI increases during disease course in female MS patients in a time-dependent and disability-independent manner.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Serum uric acid level in patients with relapsing-remitting multiple sclerosis
    Ashtari, Fereshteh
    Bahar, Mohammadali
    Aghaei, Maryam
    Zahed, Arash
    JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (05) : 676 - 678
  • [43] Quantitative assessment of brain iron by R2* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis
    Khalil, M.
    Enzinger, C.
    Langkammer, C.
    Tscherner, M.
    Wallner-Blazek, M.
    Jehna, M.
    Ropele, S.
    Fuchs, S.
    Fazekas, F.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (09) : 1048 - 1054
  • [44] Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis
    Acaster, S.
    Swinburn, P.
    Wang, C.
    Stemper, B.
    Beckmann, K.
    Knappertz, V.
    Pohl, C.
    Sandbrink, R.
    Gondek, K.
    Edan, G.
    Kappos, L.
    Freedman, M.
    Hartung, H-P
    Arnason, B.
    Comi, G.
    Filippi, M.
    Jeffery, D.
    O'Connor, P.
    Cook, S.
    Lloyd, A. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (12) : 1504 - 1513
  • [45] Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis
    Bergsland, N.
    Horakova, D.
    Dwyer, M. G.
    Dolezal, O.
    Seidl, Z. K.
    Vaneckova, M.
    Krasensky, J.
    Havrdova, E.
    Zivadinov, R.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2012, 33 (08) : 1573 - 1578
  • [46] Immune-cell BDNF expression in treatment-naive relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy
    Kalinowska-Lyszczarz, Alicja
    Pawlak, Mikolaj A.
    Wyciszkiewicz, Aleksandra
    Osztynowicz, Krystyna
    Kozubski, Wojciech
    Michalak, Slawomir
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2018, 52 (04) : 483 - 489
  • [47] Relationship between cognition and working hours in people with clinically isolated syndrome and early relapsing-remitting multiple sclerosis
    Jongen, P.
    Wesnes, K.
    Van Geel, B.
    Pop, P.
    Sanders, E.
    Schrijver, H.
    Visser, L.
    Gilhuis, J.
    Sinnige, O.
    Brands, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 33 - 34
  • [48] Comparison of NEDA3 at one year between alemtuzumab and natalizumab in treatment-naive relapsing-remitting multiple sclerosis patients.
    Gomez, A.
    Rodriguez, F.
    Chico, J. L.
    Sanchez Sanchez, A.
    Natera, E.
    Sainz de la Maza, S.
    Villar Guimerans, L. M.
    Buisan Catevilla, F. J.
    Costa-Frossard Franca, L.
    Masjuan, J.
    Monreal, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 493 - 493
  • [49] Olfactory Dysfunction and Cognition in Radiologically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
    Arici Duz, Ozge
    Saatci, Ozlem
    Karakulak, Ece Zeynep
    Birday, Erkingul
    Hanoglu, Lutfu
    EUROPEAN NEUROLOGY, 2021, 84 (03) : 175 - 182
  • [50] Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis
    Hakansson, Irene
    Gouveia-Figueira, Sandra
    Ernerudh, Jan
    Vrethem, Magnus
    Ghafouri, Nazdar
    Ghafouri, Bijar
    Nording, Malin
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2018, 138 : 41 - 47